Outpacing
cancer starts with early detection
Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.
Outpacing
cancer starts with early detection
Detecting cancer early can make a world of difference. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw.
A novel approach to screening
Freenome’s intelligent screening platform uses multiomics technology to detect cancer in its earliest, most treatable stages.
Powered by a rigorous clinical program
Our research programs drive discovery, development, and validation of our early cancer detection tests.
Multi-disciplinary leadership with purpose
We bring together passionate creators and ambitious builders. Together, we are relentless in pushing for what’s possible in early cancer detection.
Join our team
Are you ready to make a significant impact? Explore our job openings and see how your skills can help us redefine the future of cancer screening.
Outpacing cancer starts with early detection
Outpacing cancer starts with early detection
Cancer screening should be simple, accessible and effective. Freenome is developing blood-based screening tests designed to detect cancer at its earliest, most treatable stages — helping expand access to screening through the ease of a standard blood draw.
A personalized approach to screening
We believe cancer screening should recognize that every person and every cancer is different. Our Personalized Cancer Detection approach combines blood-based testing with advanced multiomics to deliver more individualized, data-driven screening designed to improve accessibility and performance.
AI/ML-powered intelligence
SimpleScreen: making cancer screening easy and accessible
Freenome’s portfolio of SimpleScreen blood-based screening tests is how we deliver Personalized Cancer Detection – screening as unique as each individual patient.
Learn more about our SimpleScreen™ CRC, the first offering in what will be an expanding portfolio designed to address a broad range of patient risks and screening needs
Building the future of early detection
Since our founding in 2014, Freenome has been building the future of early cancer detection by combining cutting-edge science, advanced AI and machine learning technology, and bold thinking. Discover the vision, values and team behind Freenome’s mission to change how cancer is detected.